Complement and platelets : prothrombotic cell activation requires membrane attack complex-induced release of danger signals
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Complement activation in the diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) results in cytolysis and fatal thrombotic events, which are largely refractory to anticoagulation and/or antiplatelet therapy. Anticomplement therapy, however, efficiently prevents thrombotic events in PNH and aHUS, but the underlying mechanisms remain unresolved. We show that complement-mediated hemolysis in whole blood induces platelet activation similarly to activation by adenosine 5'-diphosphate (ADP). Blockage of C3 or C5 abolished platelet activation. We found that human platelets failed to respond functionally to the anaphylatoxins C3a and C5a. Instead, complement activation did lead to prothrombotic cell activation in the whole blood when membrane attack complex (MAC)-mediated cytolysis occurred. Consequently, we demonstrate that ADP receptor antagonists efficiently inhibited platelet activation, although full complement activation, which causes hemolysis, occurred. By using an established model of mismatched erythrocyte transfusions in rats, we crossvalidated these findings in vivo using the complement inhibitor OmCI and cobra venom factor. Consumptive complement activation in this animal model only led to a thrombotic phenotype when MAC-mediated cytolysis occurred. In conclusion, complement activation only induces substantial prothrombotic cell activation if terminal pathway activation culminates in MAC-mediated release of intracellular ADP. These results explain why anticomplement therapy efficiently prevents thromboembolisms without interfering negatively with hemostasis.
| Errataetall: |
CommentIn: Blood Adv. 2023 Oct 24;7(20):6364-6366. - PMID 37874560 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Blood advances - 7(2023), 20 vom: 24. Okt., Seite 6367-6380 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mannes, Marco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Complement Membrane Attack Complex |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 10.01.2024 published: Print CommentIn: Blood Adv. 2023 Oct 24;7(20):6364-6366. - PMID 37874560 Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2023010817 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359298745 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359298745 | ||
| 003 | DE-627 | ||
| 005 | 20240114233336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023010817 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1255.xml |
| 035 | |a (DE-627)NLM359298745 | ||
| 035 | |a (NLM)37428869 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mannes, Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complement and platelets |b prothrombotic cell activation requires membrane attack complex-induced release of danger signals |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Blood Adv. 2023 Oct 24;7(20):6364-6366. - PMID 37874560 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a Complement activation in the diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) results in cytolysis and fatal thrombotic events, which are largely refractory to anticoagulation and/or antiplatelet therapy. Anticomplement therapy, however, efficiently prevents thrombotic events in PNH and aHUS, but the underlying mechanisms remain unresolved. We show that complement-mediated hemolysis in whole blood induces platelet activation similarly to activation by adenosine 5'-diphosphate (ADP). Blockage of C3 or C5 abolished platelet activation. We found that human platelets failed to respond functionally to the anaphylatoxins C3a and C5a. Instead, complement activation did lead to prothrombotic cell activation in the whole blood when membrane attack complex (MAC)-mediated cytolysis occurred. Consequently, we demonstrate that ADP receptor antagonists efficiently inhibited platelet activation, although full complement activation, which causes hemolysis, occurred. By using an established model of mismatched erythrocyte transfusions in rats, we crossvalidated these findings in vivo using the complement inhibitor OmCI and cobra venom factor. Consumptive complement activation in this animal model only led to a thrombotic phenotype when MAC-mediated cytolysis occurred. In conclusion, complement activation only induces substantial prothrombotic cell activation if terminal pathway activation culminates in MAC-mediated release of intracellular ADP. These results explain why anticomplement therapy efficiently prevents thromboembolisms without interfering negatively with hemostasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Complement Membrane Attack Complex |2 NLM | |
| 700 | 1 | |a Pechtl, Veronika |e verfasserin |4 aut | |
| 700 | 1 | |a Hafner, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Dopler, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Eriksson, Oskar |e verfasserin |4 aut | |
| 700 | 1 | |a Manivel, Vivek Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Wohlgemuth, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Messerer, David Alexander Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Schrezenmeier, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Ekdahl, Kristina N |e verfasserin |4 aut | |
| 700 | 1 | |a Nilsson, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobsen, Eva-Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Hoenig, Manfred |e verfasserin |4 aut | |
| 700 | 1 | |a Huber-Lang, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Braun, Christian K |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Christoph Q |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 7(2023), 20 vom: 24. Okt., Seite 6367-6380 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:20 |g day:24 |g month:10 |g pages:6367-6380 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023010817 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 20 |b 24 |c 10 |h 6367-6380 | ||